This study aimed to evaluate the efficacy and safety of SKB264 combined with KL-A167 as neoadjuvant therapy in early-stage high-risk ER+HER2- breast cancer patients.
Females aged 18-70 years;
Pathologically confirmed invasive ductal breast cancer and untreated previously；
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1;
Life expectancy ≥3 months;
Inflammatory BC；
Has multi-centric breast cancer (presence of more than 1 tumor in different quadrants of the breast).
Has bilateral invasive breast cancer.
Has metastatic (stage IV) breast cancer.